All Clinical Studies Tagged: diarrhea

Icon
EFFICIENCY AND SAFETY OF ENTEROSGEL (POLYMETHYLSILOXANE POLYHYDRATE) IN THE TREATMENT OF IRRITABLE BOWEL SYNDROM, 2015

E.I. Tkachenko, E.B. Avalueva, E.V. Skazyvaeva, S.V. Ivanov, A.V. Pushkina, I.V. Lapinskii

The study of efficiency and safeťy of application of Enterosgel administered for tfeatment of patients with diarrhea-predominant irritable bowel syndrome had demonstrated safety and efficiency of the study medication.
Evaluation according to GSRS showed significant reduction on the scales of abdominal pain, diarrhea syndrome, dyspeptic syndrome as well as on the total measure scale. Accorcling to EGG. while studying MEA, a tendency towards normalization of GIT motor-evacuation function is evident.

Icon
CHOICE OF AN ADEQUATE THERAPY REGIMEN FOR ACUTE ENTERIC INFECTIONS IN CHILDREN: RESULTS OF A RANDOMIZED TRIAL, 2016

T.A. RUZHENTSOVA, A.V. GORELOV, A.A. PLOSKIREVA

The paper shows the necessity of choosing an enterosorbent for acute enteric infection (AEI) in children. It presents the basic properties of polymethylsiloxane polyhydrate as one of the drugs for enterosorption.

Icon
ENTEROSGEL COLUMBIA LECTURE, 2016 (Part 1)

A.V.Khovanov
Innovative Gastro-absorption method. A novel cleansing system in prevention and treatment.

Icon
ENTEROSGEL COLUMBIA LECTURE, 2016 (Part 2)

A.V.Khovanov
Innovative Gastro-absorption method. A novel cleansing system in prevention and treatment.

Icon
SILICEA GASTROINTESTINAL GEL IMPROVES GASTROINTESTINAL DISORDERS: A NON-CONTROLLED, PILOT CLINICAL STUDY, 2011

B. Uehleke, M. Ortiz and R. Stange

Silicea Gastrointestinal Gel might be suitable for uses extending beyond treatment of acute gastrointestinal disorders caused by pathogens. Improvement of various gastrointestinal symptoms in the course of treatment was documented for all patient subgroups, especially in patients suffering from GERD and IBS. Diarrhea without cramps was the single symptom which showed the most significant improvements.

The maximum effect was observed after several weeks of treatment, with a marked improvement frequently noticeable already after 3 weeks; a further improvement was seen after 6 weeks, and it was observed that there was a progressive reduction of symptoms during treatment until the end of the observation period.

It is remarkable that responder rates of approximately 30–50% were found in patients who have suffered for years from functional gastrointestinal disorders which might be regarded as therapy-refractory. These patients are highly gratifying for such a simple and well-tolerated medical device. We cannot exclude the results as mainly driven by unspecific placebo-effects.

Thus the results of this prospective, observational pilot study forma valuable basis for conducting more comprehensive controlled studies in patients with functional gastrointestinal diseases, focusing on diarrhea, GERD, and IBS.

Icon
EUROPEAN SOCIETY FOR PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY, AND NUTRITION/EUROPEAN SOCIETY FOR PEDIATRIC INFECTIOUS DISEASES EVIDENCE-BASED GUIDELINES FOR THE MANAGEMENT OF ACUTE GASTROENTERITIS IN CHILDREN IN EUROPE: UPDATE 2014

Alfredo Guarino, Shai Ashkenazi, Dominique Gendrel, Andrea Lo Vecchio, Raanan Shamir, Hania Szajewska

Gastroenteritis severity is linked to etiology, and rotavirus is themost severe infectious agent and is frequently associated with dehydration. Dehydration reflects severity and should be monitored by established score systems. Investigations are generally not needed. Oral rehydration with hypoosmolar solution is the major treatment and should start as soon as possible. Breast-feeding should not be interrupted. Regular feeding should continue with no dietary changes including milk. Data suggest that in the hospital setting, in non–breast-fed infants and young children, lactose-free feeds can be considered in the management of gastroenteritis. Active therapy may reduce the duration and severity of diarrhea. Effective interventions include administration of specific probiotics such as Lactobacillus GG or Saccharomyces boulardii, diosmectite or racecadotril. Anti-infectious drugs should be given in exceptional cases. Ondansetron is effective against vomiting, but its routine use requires safety clearance given the warning about severe cardiac effects. Hospitalization should generally be reserved for children requiring enteral/parenteral rehydration; most cases may be managed in an outpatients setting. Enteral rehydration is superior to intravenous rehydration. Ultrarapid schemes of intravenous rehydration are not superior to standard schemes and may be associated with higher readmission rates.

Icon
COLLECTION OF RESEARCH PAPERS. ENTEROSGEL RESEARCHES, 2015

Dzyublik I, Shunko Em, Barbova A. Clinical efficacy of Enterosgel in treatment of rotovirus infections in newborns
Gorodetsky, Tebechevsky F Clinical efficacy of Enterosgel in treatment of patients with hepatitis A
Tkachenko E., Avalueva E. The Clinical Efficacy and safety of Enterosgel in the treatment of diarrhoea-dominant irritable bowel syndrome.
Tkachenko E., Avalueva E. The Clinical Efficacy and safety of Enterosgel in the treatment of Helicobacter Pylori – associated chronic gastroduodentis
Astahov V., Gusev V. The Clinical Efficacy and safety of Enterosgel in complex prevention of fetoplacental dysfunction in pregnant women with earlier syphilis
Usenko D., Gorelov A. The Clinical Efficacy of Enterosgel, in treatment of intestinal infections in chidren with atopic dermatitis.
Radchenko V., Seliverstov P. The Clinical Efficacy and safety of Enterosgel in treatment of predialysis Cronic Renal Falure (CRF) patients.
Nakhashova V. The Clinical Efficacy of Enterosgel in treatment of patients with Chronic Pancreatitis
Karlyichuk A., Kulachek F. The Clinical Efficacy of Enterosgel in complex treatment and prophylaxis of post-operative intraperitoneal in complication of acute cholecystitis
Moroz L., Paliy M. Use of enterosorbent Enterosgel in complex therapy of acute viral hepatitis B with concomitant intestinal dysbiosis
Sokolov E., Majev I. Clinical efficacy of Enterosgel in patients with digestive system-relative pathology.
Paliy I., Tchernobroviy V. Clinical efficacy of Enterosgel in complex treatment of intestinal dysbiosis
Yurchenko A., Nikolaev V. Clinical efficacy of Enterosgel in treatment of intoxication and diarrhoea in patients with AIDS during antiretroviral therapy. 

Icon
COLLECTION OF RESEARCH PAPERS. GASTROENTEROLOGY: NEW APPROACHES, 2014

Paliy I.G., Reznichenko I.G. A Modern View on the Issue of Enterosorption: Choosing the O ptimal Drug
Tkach S.M. Effectiveness of Enterosorbent Enterosgel in Combined Anti-Helicobacter Therapy for Patients with Peptic Ulcer Disease
Osadchaya O.I., Boyarskaya A.M. Clinical Effectiveness of Enterosorption in Reduction of Endogenous Intoxication Syndrome in Patients with Nonspecific Ulcerative Colitis
Osadchaya O.I., Shmatova E.A., Boyarskaya A.M. Role of Detoxification Therapy in Maintaining Toxin-binding Capacity of Peripheral Blood Albumin in Patients with Alcoholic Liver Disease
Zaytseva N.V., Aminova A.I., Akatova A.A., Minchenko Ye. Yu. Peculiarities of Eradication Therapy for Chronic H. pylori-associated Gastroduodenitis in Children Living in Ecologically Unfavorable Conditions
Fedorova O.V., Fedulova E.N., Tutina O.A., Korkotashvili L.V. Endogenous Intoxication in Inflammatory Bowel Disease in Children: Substantiation of Detoxification Therapy Using Enterosorption Method
Boyarskaya A.M., Osadchaya O.I., Zhernov A.A., Kovalenko O.N.Use of Enterosorbent Enterosgel in Combination Treatment of Intestinal Dysbiosis in Children with Burn Disease
Enterosgel® in Gastroenterology: Posology and Method of Administration
Dosage and Administration of Enterosgel® for the Treatment of Acute Diarrhea 

 

Icon
SINGLE-CENTER, PROSPECTIVE, OPEN, CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ENTEROSGEL DESIGNATED TO TREAT DIARRHEA-DOMINANT IRRITABLE BOWEL SYNDROME, 2014

Tkachenko E.I., Avalueva E.B., Skazyvaeva E.V., Ivanov S.V., Lapinskii I.V., Pushkina A.V.

CONCLUSIONS
– Enterosgel® has a positive effect on the clinical performance, reducing abdominal pain severity and normalizing stool frequency in D-IBS patients, thus contributing to the harmonization of quality of life.
– On the background of administration of Enterosgel® in D-IBS patients, a decrease of GIT dysbiosis signs is observed, improving the quantitative and qualitative microflora composition of thecolon.
– Enterosgel® is well-tolerated, safe and can be recommended for use in D-IBS patients.
– Treatment regimens that can be recommended for use in patients with D-IBS: 22.5 g of the paste with the active substance polymethylsiloxane polyhydrate 3 times a day 1 hour after meal orally for 3 consecutive weeks (paste dose should be dissolved in 200 ml of cool boiled water or washed down with at least 200 ml of cool boiled water).